At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Suresh Kumarasamy, MBBS(Mysore), MObGyn(Mal), FRCOG(Lond), FRCP(Ire), AM, from Gleneagles Penang, Penang, Malaysia, reviews advances in the development of new therapeutic approaches for the management of patients with ovarian cancer, including the available data and future directions of new agents, olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, and bevacizumab, an anti-VEGF antibody.
Olaparib and bevacizumab: On the horizon for treating ovarian cancer
25th May 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?